Literature DB >> 11044109

Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

S P Singh1, B Tomkowicz, D Lai, M Cartas, S Mahalingam, V S Kalyanaraman, R Murali, A Srinivasan.   

Abstract

Vpr, encoded by the human immunodeficiency virus type 1 genome, contains 96 amino acids and is a multifunctional protein with features which include cell cycle arrest at G(2), nuclear localization, participation in transport of the preintegration complex, cation channel activity, oligomerization, and interaction with cellular proteins, in addition to its incorporation into the virus particles. Recently, structural studies based on nuclear magnetic resonance and circular dichroism spectroscopy showed that Vpr contains a helix (HI)-turn-helix (HII) core at the amino terminus and an amphipathic helix (HIII) in the middle region. Though the importance of helical domains HI and HIII has been defined with respect to Vpr functions, the role of helical domain HII is not known. To address this issue, we constructed a series of mutants in which the HII domain was altered by deletion, insertion, and/or substitution mutagenesis. To enable the detection of Vpr, the sequence corresponding to the Flag epitope (DYKDDDDK) was added, in frame, to the Vpr coding sequences. Mutants, expressed through the in vitro transcription/translation system and in cells, showed an altered migration corresponding to deletions in Vpr. Substitution mutational analysis of residues in HII showed reduced stability for VprW38S-FL, VprL42G-FL, and VprH45W-FL. An assay involving cotransfection of NLDeltaVpr proviral DNA and a Vpr expression plasmid was employed to analyze the virion incorporation property of Vpr. Mutant Vpr containing deletions and specific substitutions (VprW38S-FL, VprL39G-FL, VprL42G-FL, VprG43P-FL, and VprI46G-FL) exhibited a negative virion incorporation phenotype. Further, mutant Vpr-FL containing deletions also failed to associate with wild-type Vpr, indicating a possible defect in the oligomerization feature of Vpr. Subcellular localization studies indicated that mutants VprDelta35-50-H-FL, VprR36W-FL, VprL39G-FL, and VprI46G-FL exhibited both cytoplasmic and nuclear localization, unlike other mutants and control Vpr-FL. While wild-type Vpr registered cell cycle arrest at G(2), mutant Vpr showed an intermediary effect with the exception of VprDelta35-50 and VprDelta35-50-H. These results suggest that residues in the HII domain are essential for Vpr functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044109      PMCID: PMC110939          DOI: 10.1128/jvi.74.22.10650-10657.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Epitope-based assay to determine the efficiency of cleavage by HIV-1 protease.

Authors:  D Serio; I T Weber; R W Harrison; J M Louis; A Srinivasan
Journal:  Biotechniques       Date:  1999-02       Impact factor: 1.993

2.  Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.

Authors:  D Serio; T A Rizvi; M Cartas; V S Kalyanaraman; I T Weber; H Koprowski; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

3.  The carboxy-terminal domain is essential for stability and not for virion incorporation of HIV-1 Vpr into virus particles.

Authors:  S Mahalingam; M Patel; R G Collman; A Srinivasan
Journal:  Virology       Date:  1995-12-20       Impact factor: 3.616

4.  Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers.

Authors:  S C Piller; G D Ewart; A Premkumar; G B Cox; P W Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

5.  HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B.

Authors:  V Ayyavoo; A Mahboubi; S Mahalingam; R Ramalingam; S Kudchodkar; W V Williams; D R Green; D B Weiner
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

6.  Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: implications for priming of HIV-1 reverse transcription.

Authors:  L A Stark; R T Hay
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat.

Authors:  L Wang; S Mukherjee; F Jia; O Narayan; L J Zhao
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

8.  Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.

Authors:  M Bouhamdan; S Benichou; F Rey; J M Navarro; I Agostini; B Spire; J Camonis; G Slupphaug; R Vigne; R Benarous; J Sire
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.

Authors:  Y L Lu; P Spearman; L Ratner
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr.

Authors:  P Di Marzio; S Choe; M Ebright; R Knoblauch; N R Landau
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  14 in total

1.  Specific amino acids in HIV-1 Vpr are significantly associated with differences in patient neurocognitive status.

Authors:  Will Dampier; Gregory C Antell; Benjamas Aiamkitsumrit; Michael R Nonnemacher; Jeffrey M Jacobson; Vanessa Pirrone; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Tony James; Kathryn N Devlin; Tania Giovannetti; David J Libon; Zsofia Szep; Garth D Ehrlich; Brian Wigdahl; Fred C Krebs
Journal:  J Neurovirol       Date:  2016-07-11       Impact factor: 2.643

2.  Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles.

Authors:  Narasimhan J Venkatachari; Leah A Walker; Oznur Tastan; Thien Le; Timothy M Dempsey; Yaming Li; Naveena Yanamala; Alagarsamy Srinivasan; Judith Klein-Seetharaman; Ronald C Montelaro; Velpandi Ayyavoo
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

3.  HIV-1 Vpr oligomerization but not that of Gag directs the interaction between Vpr and Gag.

Authors:  Joëlle V Fritz; Denis Dujardin; Julien Godet; Pascal Didier; Jan De Mey; Jean-Luc Darlix; Yves Mély; Hugues de Rocquigny
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

4.  Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo.

Authors:  Jörg Votteler; Nicole Studtrucker; Stefan Sörgel; Jan Münch; Elke Rücker; Frank Kirchhoff; Bernhard Schick; Peter Henklein; Torgils Fossen; Karsten Bruns; Alok Sharma; Victor Wray; Ulrich Schubert
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

Review 5.  HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention.

Authors:  Michael Kogan; Jay Rappaport
Journal:  Retrovirology       Date:  2011-04-13       Impact factor: 4.602

6.  Characterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assay.

Authors:  Gaëlle Gonzalez; Sandrina DaFonseca; Elisabeth Errazuriz; Pascale Coric; Florence Souquet; Serge Turcaud; Pierre Boulanger; Serge Bouaziz; Saw See Hong
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

Review 7.  The Vpr protein from HIV-1: distinct roles along the viral life cycle.

Authors:  Erwann Le Rouzic; Serge Benichou
Journal:  Retrovirology       Date:  2005-02-22       Impact factor: 4.602

8.  The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.

Authors:  Sandrina Dafonseca; Pascale Coric; Bernard Gay; Saw See Hong; Serge Bouaziz; Pierre Boulanger
Journal:  Virol J       Date:  2008-12-23       Impact factor: 4.099

9.  The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.

Authors:  Irina Tcherepanova; Aijing Starr; Brad Lackford; Melissa D Adams; Jean-Pierre Routy; Mohamed Rachid Boulassel; David Calderhead; Don Healey; Charles Nicolette
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

10.  Development of a robust cell-based high-throughput screening assay to identify targets of HIV-1 viral protein R dimerization.

Authors:  Courtney Zych; Alexander Domling; Velpandi Ayyavoo
Journal:  Drug Des Devel Ther       Date:  2013-05-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.